The Beatson Institute for Cancer Research carries out a programme of world-class science directed at understanding key aspects of cancer cell behaviour. The Institute’s aim is to translate these discoveries into new therapies and diagnostic/prognostic tools to help cancer patients. The RNAi Screening Facility was established in January 2011, and supports these translational endeavours.
Our principle goals are to enhance efficacy of existing chemotherapeutics, and to find novel ways to target tumours with known mutations in key cancer-related pathways e.g. p53. We use synthetic lethality approaches to do this, and are also undertaking studies investigating invasion and migration to further understand the pathways promoting tumour metastasis. We use High Content Imaging extensively to quantify our phenotype(s) of interest (Operetta, Perkin Elmer).
The Beatson Institute is part of the Glasgow Centre for Cancer Research, and is core funded by CRUK.
RNAi Global Principal Investigator: